首页> 外文期刊>Cardiovascular drugs and therapy >MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216
【24h】

MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216

机译:与其前身etc-216相比,MDCO-216不诱导不利免疫刺激

获取原文
获取原文并翻译 | 示例
           

摘要

Aim of this study was to demonstrate that MDCO-216 (human recombinant Apolipoprotein A-I Milano) does not induce adverse immunostimulation, in contrast to its predecessor, ETC-216, which was thought to contain host cell proteins (HCPs) that elicited an inflammatory reaction.
机译:本研究的目的是证明MDCO-216(人重组脂蛋白AI Milano)不诱导不利免疫刺激,与其前身等级216相反,其被认为含有引发炎症反应的宿主细胞蛋白(HCP) 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号